	US 12,030,945 B2
	Variant IgG Fc polypeptides and uses thereof
Yen-Lin Chen, Cambridge, MA (US); Ryan Peckner, Berkeley, CA (US); Nathan Higginson-Scott, Hingham, MA (US); Daniela Cipolletta, Belmont, MA (US); Yanfeng Zhou, Boxborough, MA (US); Kevin Lewis Otipoby, Ashland, MA (US); and Jyothsna Visweswaraiah, Arlington, MA (US)
Assigned to Seismic Therapeutic, Inc., Cambridge, MA (US)
Filed by Seismic Therapeutic, Inc., Cambridge, MA (US)
Filed on Oct. 25, 2023, as Appl. No. 18/494,454.
Claims priority of provisional application 63/517,493, filed on Aug. 3, 2023.
Claims priority of provisional application 63/493,356, filed on Mar. 31, 2023.
Claims priority of provisional application 63/380,853, filed on Oct. 25, 2022.
Claims priority of provisional application 63/380,842, filed on Oct. 25, 2022.
Prior Publication US 2024/0132592 A1, Apr. 25, 2024
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2818 (2013.01) [C07K 16/2803 (2013.01); C07K 2317/52 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/75 (2013.01)]

30 Claims

1. An Fc polypeptide having at least 95% identity to an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 88 provided that the Fc polypeptide comprises:

a glutamic acid residue at position 237 and a glutamic acid residue at position 238, wherein the positions are according to EU numbering;

an aspartic acid residue at position 237, a glycine residue at position 238, an alanine residue at position 240, an aspartic acid residue at position 269, a glutamic acid residue at position 270, and an arginine residue at position 330, wherein the positions are according to EU numbering; or

a phenylalanine residue at position 234, a glutamic acid residue at position 235, an aspartic acid residue at position 268, a glycine residue at position 271, and an alanine residue at position 329, wherein the positions are according to EU numbering.